Fig. 4From: Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF studyChange from baseline to week 4 in HIT-6 total score by baseline acute treatment optimization subgroup based on mTOQ-4. Patients were grouped by baseline mTOQ-4 total scores into the following optimization categories: very poor (0), poor (1–5), moderate (6–7), and maximal (8). The HIT-6 total score ranges from 36 to 78, with higher scores indicating more severe headache-related impact. Epti, eptinezumab (100 mg); HIT-6, 6-item Headache Impact Test; mTOQ-4, 4-item Migraine Treatment Optimization QuestionnaireBack to article page